Value creation and sharing among universities, biotechnology and pharma.

Published on Jun 1, 2003in Nature Biotechnology31.86
· DOI :10.1038/nbt0603-618
Mark G Edwards2
Estimated H-index: 2
Fiona Murray23
Estimated H-index: 23
(MIT: Massachusetts Institute of Technology),
Robert Yu2
Estimated H-index: 2
An analysis of deal structures in biotechnology from the past 25 years reveals that universities often neglect important economic aspects in their licensing agreements.
  • References (0)
  • Citations (51)
Cited By51
#1Panos Lehouritis (UCC: University College Cork)H-Index: 6
#2Glenn Hogan (UCC: University College Cork)H-Index: 1
Last.Mark Tangney (UCC: University College Cork)H-Index: 26
view all 3 authors...
#1Charlotta Dahlborg (KI: Karolinska Institutet)H-Index: 1
#2Danielle Lewensohn (KI: Karolinska Institutet)H-Index: 1
Last.Carl Johan Sundberg (KI: Karolinska Institutet)H-Index: 33
view all 4 authors...
#1Woojin Yoon (Hanyang University)H-Index: 1
#2Diane Y. Lee (SNU: Seoul National University)H-Index: 1
Last.Jaeyong Song (SNU: Seoul National University)H-Index: 1
view all 3 authors...
View next paperObjectives, Characteristics and Outcomes of University Licensing: A Survey of Major U.S. Universities